AMUN 003
Alternative Names: AMUN-003Latest Information Update: 08 Jun 2023
At a glance
- Originator AmunBio
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunologic cytotoxicity; Transforming growth factor beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 May 2023 AmunBio has patent protection for AMUN 003 (AmunBio website, May 2023)
- 14 Apr 2023 Pharmacodynamic and adverse events data from preclinical trial in solid tumour presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 22 Nov 2022 AmunBio plans to files an IND application for solid tumors in early 2023